NCT06414798View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

February 8, 2025

Study Completion Date

February 8, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

Drug: ABBV-1088

• Oral Capsule

DRUG

Drug: Placebo for ABBV-1088

• Oral Capsule

Trial Locations (1)

60030

Acpru /Id# 264249, Grayslake

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY